(NASDAQ:LFVN) SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025.
(NASDAQ:LFVN) SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the H.C. Wainwright 27th Annual Global Investment Conference, to be held September 8-10, 2025 in New York, NY.
(NASDAQ:LFVN) SALT LAKE CITY, Aug. 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company’s Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid September 16, 2025 to all stockholders of record at the close of business on September 8, 2025.
SALT LAKE CITY, Aug. 21, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2025, after the stock market closes on Thursday, September 4, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.
Benzinga Pro data, Lifevantage (NASDAQ:LFVN) reported Q4 sales of $50.94 million. Earnings fell to a loss of $1.42 million, resulting in a 224.1% decrease from last quarter.
Lifevantage (NASDAQ:LFVN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Lifevantage will report an earnings per share (EPS) of $0.11.
